In insulin-naive adults with T2D, once-weekly icodec plus semaglutide vs insulin glargine U100 showed superior glycemic control and weight loss.
The FDA has approved Enspryng (satralizumab-mwge) for thyroid eye disease in adults, offering the first at-home subcutaneous IL-6 receptor antagonist for TED.
The amylin-based analog petrelintide achieves meaningful weight reduction for adults with obesity, according to a study.
For adults taking potassium-raising medications, greater consumption of dietary potassium as part of a DASH diet is not associated with hyperkalemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results